

# CHONDROPROTEC®

PATENTED

Polysulfated glycosaminoglycan.  
*Topical Wound Management Dressing*

Chondroprotective agents are natural substances such as glycosaminoglycans that support or enhance the connective tissue matrix and, as such, are found in the chemical composition of connective tissue and soft tissue in humans and animals. These compounds have become beneficial in the management of chronic and acute wounds. Polysulfated glycosaminoglycans rehydrate dry wounds, maintain a moist healing environment,<sup>1-2-3</sup> and protect from tissue trauma<sup>2</sup>.

## **Description:**

CHONDROPROTEC® is available in a sterile 10 mL solution containing 1000 mg of polysulfated glycosaminoglycan or a sterile 5 mL solution containing 500 mg of polysulfated glycosaminoglycan (with a preservative added). Sodium hydroxide and/or hydrochloric acid is added when necessary to adjust pH to 6.5 - 6.7.

## **Indications:**

CHONDROPROTEC® is indicated for use in the management of :

- ❖ Pressure Ulcers (Stages I-IV)
- ❖ Venous Stasis Ulcers
- ❖ First and Second Degree Burns
- ❖ Secreting and Bleeding Dermal Lesions
- ❖ Trauma Injuries
- ❖ Partial and Full Thickness Wounds
- ❖ Surgical Incisions
- ❖ Donor Sites.

## **Characteristics:**

- ❖ creates an optimal moist wound healing environment
- ❖ protects new granulation tissue
- ❖ promotes natural autolysis by rehydrating and softening necrotic tissue and eschar thereby encouraging autolytic debridement
- ❖ conforms to any wound site
- ❖ easy to apply and redress

## **Precautions and Contraindications:**

No known side effects, not intended for use as a long-term or permanent dressing. CHONDROPROTEC® is to be dispensed by prescription only.

## **Product Administration:**

CHONDROPROTEC® is a sterile solution of polysulfated glycosaminoglycan and should be handled accordingly.

\*Wounds that are contaminated and/or infected should be debrided prior to using the CHONDROPROTEC® product.

1. Irrigate wound with normal saline solution.
2. Either pour contents of vial or dispense from syringe to withdraw solution and cover wound site.
3. Cover with a non-adherent dressing such as PUF (polyurethane film) or Telfa®. Note: subsequent applications of CHONDROPROTEC® can be through the dressing as to not disturb the wound bed.
4. Reapply CHONDROPROTEC daily and redress wound site every 5-7 days or as needed.

## **Storage:**

- ❖ Store at controlled room temperature (15° – 30° C)
- ❖ Protect from freezing

## **How Supplied:**

CHONDROPROTEC® is supplied in a sterile 10 mL vial containing 1000 mg of polysulfated glycosaminoglycan (PSGAG) or a vial containing 5mL, 500 mg PSGAG.

**References:** 1. Lassus, A. Jeskahan, L., et al: Imdeen for the treatment of degenerated skin in females. Journal of Int'l Research. 19(2): 147-52. 2. Cooper, ML, Hansbrough, JF. Use of a composite skin graft composed of fibroblasts and a collagen-GAG matrix to cover full-thickness wounds. Surgery. Feb. 1991; 109(2): 198-207. 3. Breborowitz, A., et al: Glycosaminoglycan chondroitin sulfate prevent loss of ultra filtration during peritoneal dialysis in rats. Nephron. 1994; 67(3): 346-50.

**The Hymed Group Corporation, 1890 Bucknell Drive, Bethlehem, PA 18015 . TEL: (610) 865-9876, FAX (610) 691-5930.**

The information given herein is believed to be reliable. However, no guarantee is made or liability assumed. The Hymed Group Corp. does not know all of the uses to which its products may be utilized or the condition of use. Therefore, The Hymed Group Corp. makes no claims or warranty concerning the fitness or suitability of the product for a particular use or purpose other than those outlined. 9/04